Trials / Completed
CompletedNCT04455126
Preservative-free Tafluprost Eye Drops in Newly Diagnosed Patients With Glaucoma
Preservative-free Tafluprost Eye Drops in Newly Diagnosed Patients With Glaucoma: A Prospective Clinical Study
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Alexandria University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Glaucoma encompasses a collective group of optic neuropathies characterized by progressive degeneration of retinal ganglion cells and their axons, resulting in cupping, a distinctive appearance of the optic disc, and a pattern of visual loss
Detailed description
Saflutan® is the first preservative-free prostaglandin analog introduced to the Egyptian market. It contains the PG analog tafluprost. Better tolerability, higher adherence to treatment and improvement of patients' quality of life are associated with using preservative-free eye drops.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Preservative-free tafluprost eye drops | This was an open-label, non-randomized clinical study that aimed to assess the ocular signs and symptoms in 60 eyes of 30 newly diagnosed Egyptian glaucoma patients receiving preservative-free tafluprost eye drops |
Timeline
- Start date
- 2018-04-01
- Primary completion
- 2018-12-30
- Completion
- 2020-06-01
- First posted
- 2020-07-02
- Last updated
- 2020-07-02
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04455126. Inclusion in this directory is not an endorsement.